Therefore, the development of antibodies directly targeting the CD38 catalytic site with reduced cytotoxic effect should now be a priority (Chini et al, 2018) for further development of such a therapy for DMD. This evidence concerns the gene CD38 and Duchenne muscular dystrophy.